Sanofi has been significantly investing in artificial intelligence (AI) through multiple partnerships and deals, with the number of AI companies involved in drug discovery and development growing rapidly in recent years. Sanofi’s collaborations with AI companies range from predictive biomedical AI models to AI-powered drug discovery platforms. The company’s goal is to become the first pharma firm to be powered by AI at scale, helping expedite drug discovery, enhance clinical trial methods, and optimize medicine and vaccine manufacturing.
News – Masimo reports cyber incident affecting production sites – teiss
Masimo has reported a cyber incident that has impacted its production sites. The company is currently assessing the situation to understand the extent of the
